Vet World Vol.13 August-2020 Article-4
Research Article
Veterinary World, 13(8): 1517-1523
https://doi.org/10.14202/vetworld.2020.1517-1523
Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins
2. Department of Radiology, King Abdulaziz Medical City, National Guard Hospital, Riyadh, Saudi Arabia.
3. Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
4. Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, Jordan.
Background and Aim: The beta toxin is causing the most severe Clostridium perfringens-related diseases. This work was dedicated to developing a vaccine against beta toxin using C. perfringens type C (NCTC 3180).
Materials and Methods: The crude toxoid harvest contained 710 limits of flocculation (Lf)/mL. The vaccine was formulated. Each 1 mL of the final vaccine product contained at least 50 Lf/mL of beta toxoids, 0.2 mL 3% aluminum hydroxide gel (equivalent to 5.18 mg of aluminum), <0.001% W/V thiomersal, formaldehyde <0.05% W/V, and ∼0.7 mL phosphate-buffered saline (pH 7.2). The efficacy of the vaccine was evaluated by potency, stability, and safety tests.
Results: The vaccine demonstrated 24.36 IU/mL (standard deviation, ±0.56) and 14.74 IU/mL (±0.36) of neutralizing antibodies in rabbits and cattle, respectively. Indeed, these levels were above the minimum recommended by international protocols since the obtained antibody levels had 2.43- and 1.47-fold increase in both rabbits and cattle, respectively, over the minimum antitoxin level suggested by the United States Department of Agriculture. Interestingly, our formulation was capable of inducing 1.65-fold higher immune responses in rabbits than that stimulated in cattle (65% increase) with a significant difference (p<0.0001). The vaccine was stable up to 30 months. The vaccinated rabbits were suffered from a temporarily slight increase in temperatures in the first 10 h without any significant difference (p>0.05).
Conclusion: The research showed a procedure for the manufacturing process of the vaccine against C. perfringens beta toxins with a feasible quantity and the vaccine described here showed to be effective in eliciting levels of neutralizing antibodies higher than required by international standards. In addition, The vaccine was stable up to 30 months. Thus, it may represent an effective and safe for preventing C. perfringens-related diseases in rabbits and cattle, although further studies to prove its efficacy in the field on other farm animals are still needed. Keywords: beta toxin, cattle, Clostridium perfringens type C, potency, safety, stability, toxoid.
Keywords: beta toxin, cattle, Clostridium perfringens type C, potency, safety, stability, toxoid.
How to cite this article: Saadh MJ, Sa'adeh IJ, Dababneh MF, Almaaytah AM, Bayan MF (2020) Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins, Veterinary World, 13(8): 1517-1523.
Received: 06-03-2020 Accepted: 11-06-2020 Published online: 07-08-2020
Corresponding author: Mohamed J. Saadh E-mail: msaadeh@meu.edu.com
DOI: 10.14202/vetworld.2020.1517-1523
Copyright: Saadh, et al. This article is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.